The majority of TET2 mutations recorded in patients with myeloid malignancy are within regions critical for enzymatic activity suggesting they are loss of function mutations and hence TET2 is seen to be having a tumour suppressor role [1, 3]. This evidence concerns the gene TET2 and neoplasm.